Qiagen N.v. · NYSE:QGEN
Qiagen — Investor Presentation (March 2023)
19 slides from Qiagen's investor presentation, Mar 28, 2023
Slide 1: Investor Introduction First quarter 2023
Making improvements in life possible Investor Introduction First quarter 2023
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. S
Slide 3: We help advance science and improve outcomes
We help advance science and improve outcomes Our Mission Enabling access to valuable insights from molecular research to clinical healthcare Our Vision Making improvements in life possible Q1 2023 Investor Introduction 3
Slide 4: QIAGEN provides solutions to uncover molecular insights
QIAGEN provides solutions to uncover molecular insights – faster, better and more efficiently – from Sample to Insight Biological Sample to Valuable sample Insight solutions molecular insights • Sample Technologies • Advancing knowledge about the building • Assay Technologies blocks of life – DNA, R
Slide 5: QIAGEN at a glance
QIAGEN at a glance A global company with scale ~45% Americas $2.1 billion (2022 sales) Sales ~35% EMEA ~20% Asia-Pacific / Japan Highly recurring revenues Balanced customer markets ~6,200 employees known as QIAGENers ~ 88% 12% ~ ~ 50% 50% ~ Consumables and related revenues Instruments Molecular Diag
Slide 6: There is an unprecedented need for molecular research and testing
There is an unprecedented need for molecular research and testing to tackle the health challenges of our time Our knowledge about Tuberculosis is still Cancer remains a Infectious diseases the building blocks of one of the world’s leading cause of have been – and life – DNA, RNA and most significant
Slide 7: Our products are found in laboratories worldwide
Our products are found in laboratories worldwide - from young scientists to Nobel laureates Q1 2023 Investor Introduction 7
Slide 8: We are ready to serve public health needs across the globe
We are ready to serve public health needs across the globe Determined to leave no country behind with a portfolio of dedicated tests and strategic partnerships TB testing for low-resource Testing for high-risk human Sample technologies high-burden regions with papillomavirus (HPV) using supporting d
Slide 9: Our strong global presence serves both developed and emerging markets
Our strong global presence serves both developed and emerging markets Our global Direct sales in >30 and regional headquarters: Venlo Netherlands Germantown Global HQ countries Maryland Americas HQ Hilden Germany EMEA HQ Shanghai China HQ Shipping product to Singapore Asia-Pacific HQ >170 countries
Slide 10: Our Strategy: Leveraging a strong core portfolio to drive 5 Pillars of Growth
Our Strategy: Leveraging a strong core portfolio to drive 5 Pillars of Growth Expanding on solid leadership Early commercialization phases with strong growth potential Sample QuantiFERON QIAstat-Dx NeuMoDx QIAcuity technologies Leading immune Syndromic testing with Differentiated microfluidic Novel
Slide 11: Five pillars of growth: Expected trends in 2023
Five pillars of growth: Expected trends in 2023 Cumulative 2023 placements sales goals (As of Jan 2023) (CER) QIAsymphony >3,200 Sample technologies QIAcube >14,000 >$685 m EZ1 and EZ2 >5,000 QuantiFERON >$360 m QIAstat-Dx >3,000 >$95 m NeuMoDx >300 >$80 m QIAcuity digital PCR >1,300 >$70 m CER – Co
Slide 12: FY 2022: +14% CER growth in non-COVID product groups
FY 2022: +14% CER growth in non-COVID product groups Non-COVID / COVID split By product group (In $ millions at actual rates) (In $ millions at actual rates) 2022 headwinds vs. 2021 -5% -5% COVID sales in Sample (+0% CER) (+0% CER) technologies and PCR/NA amplification $2,252 $2,252 $2,142 $2,142 85
Slide 13: Reporting sales in product groups
Reporting sales in product groups QIAGEN Five pillars of growth Sample QIAcuity product groups technologies(1) digital PCR(3) QIAstat-Dx NeuMoDx QuantiFERON Sample technologies(1) Consumables and instruments used in sample collection, stabilization, storage, purification and quality control includin
Slide 14: FY 2022: Leveraging strong cash flow to build sustainable growth
FY 2022: Leveraging strong cash flow to build sustainable growth Operating cash flow Free cash flow (In $ millions) (In $ millions) Targeted investments into five pillars + 12% + 30% High level of R&D investments into menu expansion for QIAstat-Dx, NeuMoDx and QIAcuity $715 $586 586 $639 Proactively
Slide 15: Maintaining financial flexibility with appropriate leverage
Maintaining financial flexibility with appropriate leverage Structure as of December 31, 2022 Maturities of debt instruments (In $ millions) $1.91 billion $1.42 billion Cash and short-term Convertible Bonds Schuldschein Convertible investments Bonds 117 2023 2024 601 613 2027 101 113 400 $492 millio
Slide 16: Outlook: Q1 and FY 2023
Outlook: Q1 and FY 2023 Q1 2023 outlook FY 2023 outlook Net sales > $490 million CER > $2.05 billion CER Anticipated currency impact Adverse FX impact of ~ -2 p.p. +/- 0 p.p. Double-digit CER growth in non-COVID product groups Adjusted EPS ≥ $0.47 CER ≥ $2.10 CER Anticipated currency impact Adverse
Slide 17: Capital allocation: Strong balance sheet to create greater value
Capital allocation: Strong balance sheet to create greater value Investing in growth Healthy cash flow and leverage ratio trends $ Expanding test menus and millions manufacturing capacity, 700 1.6x especially in the five pillars 1.5x 600 1.4x Enhance value with M&A 500 639 Ongoing disciplined approa
Slide 18: Balance: Well-diversified business spanning attractive markets
Balance: Well-diversified business spanning attractive markets Diversified Broad Highly customer base geographic reach recurring revenues Well-balanced leadership in >6,300 QIAGENers ensuring Growing installed base Life Sciences and access to attractive markets with generating demand for Molecular D
Slide 19: Your contacts
Your contacts Phoebe Loh Senior Director Calendar Global Investor Relations Q1 2023 results May 2023 Phone: +49 2103 29 11457 Mobile: +49 152 018 11457 Annual General Meeting June 2023 E-mail: phoebe.loh@qiagen.com Q2 2023 results August 2023 Alexandra Koenig Share information Coordinator Investor R